Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.49 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10931933 | 0.87 | CA2 (0.60) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL4584838 | 0.85 | BCAT1 (0.50) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL370189 | 0.83 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL27583034 | 0.83 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL28500699 | 0.82 | PTGS2 (0.50) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL5605338 | 0.82 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3928644 | 0.81 | CA1 (0.62) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL29135554 | 0.81 | LMNA (0.58) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL209631 | 0.79 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL5174593 | 0.79 | GAA (0.46) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258847-A1 | Cholanic Acid Amides | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| EP-2044100-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008009407-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258847-A1 | Cholanic Acid Amides | NR1H4, SLC10A1, CYP46A1 | CA2 794/4885CA1 124/4885MMP1 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.